Axsome Therapeutics Stock Surges on FDA Update

Year-over-year, AXSM remains down 55%

Digital Content Manager
Jun 27, 2022 at 10:49 AM
facebook twitter linkedin


Axsome Therapeutics Inc (NASDAQ:AXSM) is surging today, after the company said it has received proposed labeling from the Food and Drug Administration (FDA) for AXS-05, its drug candidate to treat major depressive disorder. The treatment currently has a marketing application under review. At last check, the security is up 45.1% to trade at $35.48. 
 

The brokerage bunch is yet to chime in, but is already optimistic on AXSM, with eight of the 10 in coverage calling it a "strong buy." Plus, the 12-month consensus target price of $78 is a 131.4% premium to current levels. Meanwhile, short interest is up 10.3% in the last two reporting periods, and accounts for 16.1% of the stock's available float. Should some of this pessimism begin to unwind, shares could surge higher still.

Additional tailwinds could come from a shift in the options pits. Over at the International Securities Exchange (ISE), Cboe Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), AXSM sports a 50-day put/call volume ratio of 1.55 that sits higher than 93% of readings from the last 12 months. This means long puts are getting picked up at a much quicker-than-usual clip.

Drilling down to today's options activity, 6,852 and 3,014 calls have crossed the tape, which is nine times the intraday average. Most popular is the July 30 call, followed by the 12.50 put in the same series.

The equity is today trading at its highest level since May, while looking to settle above resistance from the 30-day moving average. Today's pop follows a pullback to the $20 region -- its lowest level since August -- though year-over-year AXSM remains down 55%. 

 

If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!

Schaeffer's Investment Research Stock Pick Report
 


 


 
Special Offers from Schaeffer's Trading Partners